ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, today announced the formation of its Oncology Scientific Advisory Board (SAB) to collaborate on the clinical development planning and strategy for its lead cancer drug candidate, Archexin™
